These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 8712782)

  • 21. [The function of the p53 gene suppressor in carcinogenesis].
    Sándor J; Ambrus T; Ember I
    Orv Hetil; 1995 Aug; 136(35):1875-83. PubMed ID: 7675427
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Molecular biology of tobacco smoke associated neoplasia].
    Zojer N; Fritsche R; Fiegl M; Schulte-Hermann R; Mannhalter C; Huber H
    Wien Klin Wochenschr; 1996; 108(18):574-81. PubMed ID: 9012141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. P53, cell cycle control and apoptosis: implications for cancer.
    Kastan MB; Canman CE; Leonard CJ
    Cancer Metastasis Rev; 1995 Mar; 14(1):3-15. PubMed ID: 7606818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment.
    Harris CC
    Prev Med; 1996; 25(1):10-2. PubMed ID: 8778751
    [No Abstract]   [Full Text] [Related]  

  • 25. Functional inactivation of p53 by human T-cell leukemia virus type 1 Tax protein: mechanisms and clinical implications.
    Tabakin-Fix Y; Azran I; Schavinky-Khrapunsky Y; Levy O; Aboud M
    Carcinogenesis; 2006 Apr; 27(4):673-81. PubMed ID: 16308315
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Negative immunohistochemical staining of p53 protein does not always reflect wild-type p53 gene in cancer cells.
    Horiuchi H; Kawamata H; Omotehara F; Fujii S; Fujimori T; Kuroda Y
    J Gastroenterol; 2004 Aug; 39(8):801-3. PubMed ID: 15338377
    [No Abstract]   [Full Text] [Related]  

  • 27. p53 mutation heterogeneity in cancer.
    Soussi T; Lozano G
    Biochem Biophys Res Commun; 2005 Jun; 331(3):834-42. PubMed ID: 15865939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant transformation of mature cystic teratoma to squamous cell carcinoma involves altered expression of p53- and p16/Rb-dependent cell cycle regulator proteins.
    Iwasa A; Oda Y; Kurihara S; Ohishi Y; Yasunaga M; Nishimura I; Takagi E; Kobayashi H; Wake N; Tsuneyoshi M
    Pathol Int; 2008 Dec; 58(12):757-64. PubMed ID: 19067849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinicopathologic and carcinogenetic appraisal of DNA replication error in sporadic T3N0M0 stage colorectal cancer after curative resection.
    Liang JT; Chang KJ; Chen JC; Lee CC; Cheng YM; Hsu HC; Chien CT; Wang SM
    Hepatogastroenterology; 1999; 46(26):883-90. PubMed ID: 10370632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twenty years of p53 research: structural and functional aspects of the p53 protein.
    May P; May E
    Oncogene; 1999 Dec; 18(53):7621-36. PubMed ID: 10618702
    [No Abstract]   [Full Text] [Related]  

  • 31. Anti-apoptotic activity of p53 maps to the COOH-terminal domain and is retained in a highly oncogenic natural mutant.
    Lassus P; Bertrand C; Zugasti O; Chambon JP; Soussi T; Mathieu-Mahul D; Hibner U
    Oncogene; 1999 Aug; 18(33):4699-709. PubMed ID: 10467417
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis.
    Chang F; Syrjänen S; Kurvinen K; Syrjänen K
    Am J Gastroenterol; 1993 Feb; 88(2):174-86. PubMed ID: 8424417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy.
    Resnick-Silverman L; Manfredi JJ
    J Cell Biochem; 2006 Oct; 99(3):679-89. PubMed ID: 16676359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human tumor suppressor p53 and DNA viruses.
    Collot-Teixeira S; Bass J; Denis F; Ranger-Rogez S
    Rev Med Virol; 2004; 14(5):301-19. PubMed ID: 15334538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation.
    Raveh T; Droguett G; Horwitz MS; DePinho RA; Kimchi A
    Nat Cell Biol; 2001 Jan; 3(1):1-7. PubMed ID: 11146619
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [P53 mutations, asset or disadvantage for cancer chemotherapy].
    Jacquemin-Sablon A
    Bull Cancer; 1997 Jul; 84(7):741-6. PubMed ID: 9339201
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P53 tumor suppressor gene therapy for cancer.
    Nielsen LL; Maneval DC
    Cancer Gene Ther; 1998; 5(1):52-63. PubMed ID: 9476967
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implications of the p53 tumor-suppressor gene.
    Harris CC; Hollstein M
    N Engl J Med; 1993 Oct; 329(18):1318-27. PubMed ID: 8413413
    [No Abstract]   [Full Text] [Related]  

  • 39. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
    Crowe DL; Sinha UK
    Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. p53 in recombination and repair.
    Gatz SA; Wiesmüller L
    Cell Death Differ; 2006 Jun; 13(6):1003-16. PubMed ID: 16543940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.